SUNESIS.001A

PATENT

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Erlanson et al.	) Group Art Unit 1626
App. No.	:	09/990,421	)
Filed	:	November 21, 2001	)
For	:	AN EXTENDED THETHERING APPROACH FOR RAPID IDENTIFICATION OF LIGANDS	)
Examiner	:	Unknown	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing 48 references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 24, 2002

By: _____

Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(415) 954-4114

W:\DOCS\GRD\GRD-7181.DOC011002

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY. DOCKET NO.	APPLICATION NO.
SUNESIS.001A	09/990,421
APPLICANT: Erlanson, et al.	
FILING DATE: November 21, 2001	GROUP: 1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	4,946,778	8/7/90	Ladner et al.	435	69.6	
	2.	5,422,281	6/6/95	Harris et al.	436	501	
	3.	5,571,681	11/5/96	Janda	435	7.6	
	4.	5,783,384	7/21/98	Verdine	535	6	
	5.	5,958,702	9/28/99	Benner	435	7.1	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	6.	EP 0 801 307	10/15/97	EP				
	7.	WO 95/18972	7/13/95	PCT				
	8.	WO 95/25737	9/28/95	PCT				
	9.	WO 96/13613	5/9/96	PCT				
	10.	WO 96/27605	9/12/96	PCT				
	11.	WO 97/12897	4/10/97	PCT				
	12.	WO 97/35202	11/20/97	PCT				
	13.	WO 97/43302	11/20/97	PCT				
	14.	WO 98/11436	3/19/98	PCT				
	15.	WO 98/11437	3/19/98	PCT				
	16.	WO 98/15969	4/16/98	PCT				
	17.	WO 98/25146	6/11/98	PCT				

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SUNESIS.001A	APPLICATION NO. 09/990,421
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Erlanson, et al.	
	FILING DATE November 21, 2001	GROUP 1636

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	18.	WO 98/56028	12/10/98	PCT				
	19.	WO 99/50668	10/07/99	PCT				
	20.	WO 99/50669	10/7/99	PCT				
	21.	WO 99/63944	12/16/99	PCT				
	22.	WO 00/00823	1/6/00	PCT				
	23.	WO 00/03240	1/20/00	PCT				
	24.	WO 01/02856	1/11/01	PCT				

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	25.	Abraham, D.J. et al., "How Allosteric Effectors Can Bind to the Same Protein Residue and Produce Opposite Shifts in the Allosteric Equilibrium " Biochemistry 34:150006-15020 (1995)
	26.	Boyiri, T. et al., "Bisaldehyde Allosteric Effectors as Molecular Ratchets and Probes" Biochemistry 34:15021-15036 (1995)
	27.	Bunyapaiboonsri et al., "Dynamic Deconvolution of a Pre-Equilibrated Dynamic Combinatorial Library of Acetylcholinesterase Inhibitors" ChemBioChem 2:438-444 (2001)
	28.	DeJarias et al., "Use of X-ray Co-crystal Structures and Molecular Modeling to Design Potent and Selective Non-peptide Inhibitors of Cathepsin K" J. Am. Chem. Soc. 120(35):9114-9115 (1998)
	29.	Erlanson et al., "Site-Directed ligand discovery" PNAS 97(17):9367-9372 (August 15, 2000)
	30.	Foroozesh et al. "Aryl Acetylenes as Mechanism-Based Inhibitors of Cytochrome P450-Dependent Monooxugenase Enzymes" Chem. Res. Toxicol. 10(1):91-102
	31.	Hopkins et al., "Suicide Inhibitor of Cytochrome P450 1A1 and P450 2B1" Biochem. Pharmacol. 44(4):787-796 (1992)
	32.	Huc and Lehn, "Virtual combinatorial libraries: Dynamic generation of molecular and supramolecular diversity by self-assembly" Proc. Natl. Acad. Sci. USA 94:2106-2110 (March 1997)
	33.	Jones and Thornton, "Principles of protein-protein interactions" Proc. Natl. Acad. Sci. USA 93:13-20 (January 1996)
	34.	Lehn, Jean-Marie, "Dynamic Combinatorial Chemistry and Virtual Combinatorial Libraries" Chem. Eur. J. 5(9)2455-2463 (1999)
	35.	Maly et al., "Combinatorial target-guided ligand assembly: identification of potent sybtype-selective c-Src inhibitors" PNAS 97(6):2419-2424 (March 14, 2000)

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SUNESIS.001A	APPLICATION NO. 09/990,421
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Erlanson, et al.	
	FILING DATE November 21, 2001	GROUP 1636

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	36.	Mathews et al., "N-Alkylaminobenzotriazoles as Isozyme-Selective Suicide Inhibitors of Rabbit Pulmonary Microsomal Cytochrome P-450" Mol. Pharmacol. 39(10):25-32 (1986)
	37.	Misumi et al., "The p2 ^{gag} Peptide, AEAMSQVTNTATIM, Processed for HIC-1 Pr55 ^{gag} was found to be a Suicide Inhibitor of HIV-1 Protease" Biochem. Biophys. Res. Commun. 241(2):275-280
	38.	Nicolaou et al., "Combinatorial Synthesis Through Disulfide Exchange: Discovery of Potent Psammaplin A Type Antibacterial Agents Active against Methicillin-Resistant Staphylociccus Aureus (MRSA)" Chem. Eur. J. 7(19):4280-4295 (2001)
	39.	Nicolaou et al., "Synthesis and Biological Evaluation of Vancomycin Dimers with Potent Activity against VANCOMYCIN-Resistant Bactewria: Target-Accelarated Combinatorial Synthesis" Chem Eur. J. 7(17):2824-2843 (2001)
	40.	Pollack, S. J. et al., "introduction of Nucelophines and Spectotroscopic Probes into Antibody Combining Sites" Science 242:1038-1040 (1988)
	41.	Ramstrom and Lehn, "In Situ Generation and Screening of a Dynamic Combinatorial Carbohydrate Library against Concanavalin A" ChemBioChem 1:41-48 (2000)
	42.	Sannes-Lowery et al., Trends Anal. Chem 19(8):481-491 (2000)
	43.	Shuker et al., "Discovering High-Affinity Ligands for Proteins: SAR by NMR" Science 274 (5292):1531 (Nov. 1996)
	44.	Stanojevic and Verdine, "Deconstruction of GCN4/GCRE into a monomeric peptide-DNA complex" Nature Structural Biology 2(6):450-457 (June 6, 1995)
	45.	Thompson et al., " Design of potent and selective human cathepsin K inhibitors that span the active site". Proc. Natl. Acad. Sci USA 94:14249014254 (1997)
	46.	Wetterau et al., "An MTP Inhibitor That Normalizes Atherogenic Lipprotein Levels in WHHL Rabbists" Science 282:751-754 (October 23, 1998)
	47.	Woodcroft et al., "N-Aralkylated derivatives of 1-aminobenzotriazole as isozyme-selective mechanism-based inhibitors of guinea pig hepatic cytochrome P-450 dependent monooxygenase activity" Can J. Physiol. Pharmacol. 68(9):1278-1285 (1990)
	48.	Zhang et al., "Covalent Modification and Active Site-Directed Inactivation of a low Molecular Weight Phosphotyrosyl Protein Phosphatase" Biochemistry 31(6):1701-1711 (1992)

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.